A Cost–Consequence Analysis of Preemptive SLCO1B1 Testing for Statin Myopathy Risk Compared to Usual Care

There is a well-validated association between SLCO1B1 (rs4149056) and statin-associated muscle symptoms (SAMS). Preemptive SLCO1B1 pharmacogenetic (PGx) testing may diminish the incidence of SAMS by identifying individuals with increased genetic risk before statin initiation. Despite its potential c...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunette, Charles A., Dong, Olivia M., Vassy, Jason L., Danowski, Morgan E., Alexander, Nicholas, Antwi, Ashley A., Christensen, Kurt D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624003/
https://www.ncbi.nlm.nih.gov/pubmed/34834475
http://dx.doi.org/10.3390/jpm11111123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8624003/
https://www.ncbi.nlm.nih.gov/pubmed/34834475
http://dx.doi.org/10.3390/jpm11111123

Ejemplares similares